TROV News Alert Trovagene Inc (TROV) 4.27 12/17/2014 01:29:3

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Trovagene Inc (TROV) 4.27 $TROV

Trovagene Announces Presentation of Clinical Data at the 56th American Society of Hematology Annual Meeting
PR Newswire - Thu Dec 04, 8:05AM CST
Trovagene, Inc. (NASDAQ: TROV), today announced that clinical data will be presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place December 6-9, 2014 at the Moscone Center in San Francisco. The clinical data highlight the use of Trovagene's Precision Cancer MonitoringSM technology for the determination of mutational status and longitudinal monitoring of disease dynamics from both urine and plasma cell-free DNA, and will be presented by David Hyman, M.D., Memorial Sloan-Kettering Cancer Center.
TROV: 4.27 (+0.03)

Trovagene to Present at 26th Annual Piper Jaffray Healthcare Conference
PR Newswire - Wed Nov 26, 8:05AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the 26th Annual Piper Jaffray Healthcare Conference.
TROV: 4.27 (+0.03)

TrovaGene Cancer Technology Detects KRAS Mutation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 21, 4:35PM CST
TrovaGene, Inc. (TROV) recently unveiled clinical study results that reflect the capability of its Precision Cancer Monitoring technology in detecting and monitoring KRAS mutation in circulating tumor DNA (ctDNA).
TROV: 4.27 (+0.03), ANIP: 55.08 (+1.32), AMAG: 40.30 (+1.29), AFFX: 8.90 (+0.10)

Trovagene Releases Clinical Study Results for the Detection and Monitoring of KRAS Mutations in Circulating Tumor DNA of Colorectal Cancer Patients
PR Newswire - Thu Nov 20, 8:08AM CST
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today clinical study results highlighting the Company's ability to detect and quantitate KRAS mutations in blood and urine samples from patients with advanced colorectal cancer. The data, generated using Trovagene's Precision Cancer Monitoring technology, show that quantitative changes of mutational signals in blood and urine are highly correlated and further establish the clinical applicability of a simple urine sample for cancer monitoring. The clinical study was conducted in collaboration with Genomac International, a cancer genomic research center based in Prague, Czech Republic. Trovagene's Chief Scientific Officer, Mark Erlander, Ph.D., presented the study results at the EORTC-NCI-AACR International Symposium on Molecular Targets and Therapeutics Meeting in Barcelona, Spain.
TROV: 4.27 (+0.03)

Trovagene to Present at Upcoming Healthcare Conferences
PR Newswire - Wed Nov 12, 7:15AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D., is scheduled to present a corporate overview at the following 2014 healthcare conferences: the Stifel 2014 Healthcare Conference and the Canaccord Genuity Medical Technologies and Diagnostics Forum. Each presentation will be webcast, and replays of each will be available at www.trovagene.com and archived for 90 days.
TROV: 4.27 (+0.03)

TrovaGene's (TROV) CEO Antonius Schuh on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 8:34PM CST

TROV: 4.27 (+0.03)

TrovaGene misses by $0.03
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:04PM CST

TROV: 4.27 (+0.03)

Trovagene, Inc. Announces Third Quarter 2014 Financial Results
PR Newswire - Thu Nov 06, 3:05PM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and nine months ended September 30, 2014.
TROV: 4.27 (+0.03)

What's in Store for TrovaGene (TROV) This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 2:40PM CST
TrovaGene Inc. (TROV) is set to report third-quarter 2014 results on Nov 6.
MACK: 10.08 (+0.20), TROV: 4.27 (+0.03), PTCT: 48.42 (-2.03), HSIC: 132.40 (+0.86)

Trovagene Schedules Release of Third Quarter 2014 Financial Results and Investor Conference Call
PR Newswire - Wed Oct 29, 7:10AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the third quarter and the nine months ended September 30, 2014 on Thursday, November 6, 2014 at 4:00 p.m. Eastern Standard Time (1:00 p.m. Pacific Standard Time).
TROV: 4.27 (+0.03)

Clinical Study Using Trovagene's Precision Cancer Monitoring Platform Published in Cancer Discovery
PR Newswire - Mon Oct 27, 7:10AM CDT
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, today announced the publication of clinical study results in a peer-reviewed journal, Cancer Discovery, featuring the Company's precision cancer monitoring technology and its ability to non-invasively determine oncogene mutation status and monitor response to BRAF inhibitor therapy in patients with histiocytic disease, a malignancy often associated with BRAF mutations. Study investigator Eli L. Diamond, M.D., a neuro-oncologist at Memorial Sloan Kettering Cancer Center, will present the clinical results at the 30th Annual Histiocyte Society Meeting on October 28 in Toronto, Canada.
TROV: 4.27 (+0.03)

Trovagene to Present at 13th Annual BIO Investor Forum
PR Newswire - Mon Oct 06, 3:30PM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. will be presenting at the 13th Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 13th Annual BIO Investor Forum features leading private and emerging public companies. The meeting will take place October 7-8, 2014 at the Palace Hotel in San Francisco, California.
TROV: 4.27 (+0.03)

Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium
PR Newswire - Wed Oct 01, 7:05AM CDT
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Eli Diamond, MD, Assistant Attending Neurologist at Memorial Sloan Kettering Cancer Center (MSK), presented clinical data from an ongoing study demonstrating the utility of Trovagene's precision cancer monitoring platform for the determination of oncogene mutational status in cell-free DNA obtained from a liquid biopsy. The results were presented to both treating physicians and patients at the ECD Global Alliance's Second International Medical Symposium, in collaboration with the National Institutes of Health (NIH), and expand upon clinical data presented earlier this year at the American Society of Clinical Oncology (ASCO) Annual Meeting.
TROV: 4.27 (+0.03)

Cancer Geneticist, Alberto Bardelli, Ph.D., Joins Trovagene's Scientific Advisory Board
PR Newswire - Wed Sep 17, 7:05AM CDT
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Alberto Bardelli, Ph.D., has joined the Company's Scientific Advisory Board. Dr. Bardelli was among the first to identify mutations in the kinase genes that are associated with colorectal cancer and other malignancies. Currently, he is at the Department of Oncology, Torino Medical School, Institute for Cancer Research in Candiolo, Italy.
TROV: 4.27 (+0.03)

Can The Uptrend Continue for TrovaGene (TROV)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 7:49AM CDT
Can The Uptrend Continue for TrovaGene (TROV)?
TROV: 4.27 (+0.03)

Increased Earnings Estimates Seen for TrovaGene (TROV): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 7:47AM CDT
TrovaGene has been witnessing a positive trend in its earnings estimate front and its share price has been increasing for past 4 weeks
TROV: 4.27 (+0.03)

How TrovaGene (TROV) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 7:36AM CDT
TrovaGene might be an intriguing choice for investors right now as it is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
TROV: 4.27 (+0.03)

TrovaGene (TROV) Jumps: Stock Rises 9.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 8:18AM CDT
TrovaGene, Inc. (TROV) was a big mover last session, as the company saw its shares rise over 9% on the day.
CBPO: 62.85 (-2.19), CBM: 23.35 (+0.01), TROV: 4.27 (+0.03), GILD: 100.46 (-2.70)

Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics
PR Newswire - Tue Aug 26, 7:24AM CDT
Trovagene, Inc. (NASDAQ: TROV) presented data at the Next Generation Dx Summit; Moving Assays to the Clinic with an oral presentation entitled "Targeted Detection and Monitoring of Cell Free Tumor DNA in Urine." In this presentation Trovagene reported the analytical component of its Precision Cancer Monitoring (PCM) platform and results from several studies demonstrating high clinical sensitivity for the detection of tumor DNA mutations from urine samples of cancer patients. The PCM platform uses a proprietary urinary DNA extraction process and mutant tumor DNA enrichment methodologies coupled to next generation sequencing and proprietary bio-informatic analyses. The PCM platform enables translational studies for the demonstration of high clinical sensitivity, quantitative assessment of mutational copy levels and subsequent utility for urinary-based cell-free tumor DNA diagnostics.
TROV: 4.27 (+0.03)

Clinical Results Presented for Trovagene's Urine-Based High-Risk HPV Assay.
PR Newswire - Mon Aug 25, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that results from two independent clinical studies were presented at the 29th International Papillomavirus (IPV) Conference. Results from both pilot studies consistently demonstrated that the Company's urine-based assay for the detection of high-risk HPV had high sensitivity (greater than 90%) for identifying women with high grade cervical intraepithelial neoplasia (CIN2/3). Assay performance was comparable to traditional HPV testing with commercially available tests in patient-matched cervical samples. In one of these studies, urine collection has been examined to establish standardization of urine as a clinical specimen for high-risk HPV testing.
TROV: 4.27 (+0.03)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 176

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 143

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 142

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 214

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 196

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 136

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 76

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 126

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 198

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading

Top 5 Most Recently Viewed Articles

Breaker’s TruSend™: A Game Changer in Email Marketing

Updated Category News Views 142

Breaker’s TruSend™: A Game Changer in Email Marketing In the fast-evolving world of marketing, email continues to hold its ground as a vital communication tool. Breaker has recognized the challenges marketers face with fragmented tech stacks and has introduced TruSend™, a robust email distribution platform. This innovation streamlines the email marketing process,...

Continue Reading
DigiKey and Qorvo Collaborate to Enhance Global Distribution

Updated Category News Views 151

DigiKey and Qorvo Forge Strategic Distribution Partnership DigiKey, a prominent global distributor known for its vast selection of technical components and automation products, has entered into a vital distribution agreement with Qorvo®, a leader in connectivity and power solutions. This collaboration aims to boost the availability and delivery speed of Qorvo's...

Continue Reading
Lloyds Bank's Financial Insights for 2025: A Comprehensive Review

Updated Category News Views 345

Overview of Lloyds Bank plc's 2025 Half-Year Results Lloyds Bank plc, a prominent player in the financial services sector, has released its half-year results for 2025, demonstrating resilience and strategic agility. As a member of the Lloyds Banking Group, it continues to show its commitment to delivering value to its stakeholders and customers. Key Financial Highlights...

Continue Reading
Advansor's Latest CO2 Enclosure Solutions Revolutionize Climate Control

Updated Category News Views 97

Advansor Introduces a New Range of CO2 Enclosures Advansor, a leading name in climate solutions, has recently unveiled an innovative line of CO2 enclosures tailored for supermarkets, cold storage facilities, and industrial applications. These enclosures are designed to simplify on-site installations and offer flexible options for outdoor placement. This groundbreaking...

Continue Reading
LG Innotek's Revolutionary Automotive AP Module Enhances Mobility

Updated Category News Views 220

LG Innotek's Innovative Entry into Automotive Semiconductor Market LG Innotek has taken a significant step into the automotive semiconductor component market with the launch of its Automotive Application Processor Module (AP Module). This move comes in response to a growing demand for sophisticated automotive technologies, particularly in the realm of Advanced Driver...

Continue Reading